![](https://servier.com.au/wp-content/uploads/sites/36/2024/07/240313_20TALK-X-CLOUD-GP-SERIES-3_R2.mp4.00_00_11_20.Still004-150x150.png)
Confident Conversations
Employees
Countries in which
the Group’s medicines
are distributed
Over 20% of revenue from
brand-name medicines invested
in R&D each year
in revenue in 2021/2022
including €3.7 billion for brand-name medicines and
€1.2 billion for generic activities
Oncology,
Neuroscience,
Immuno-inflammation, and
Cardio-metabolism